SNY -Sanofi-Aventis SA (ADR) (NYSE Stock)

[b_radlewis]

Current price: 31.51
Dividend Yield 5.16%
Declared Dividend 1.6273
Ex-Dividend Date 5/17/10
Dividend Payable Date 6/14/10

If you want in on this stock you need in on Monday at the latest. So far it looks like I will be on this but my research is still not done.

[BadThad]

Looks good technically, it's over-sold and trading below the 20MA and well below the 200MA. However, today is the EX date and it's a huge divy at $1.63....this might come falling down more....and fast.

[BadThad]

Couldn't resist, I'm in at $30.00....this is a good company from my DD and the PPS is way, way down near the 52-wk low.

[BadThad]

Oh.....thanks for the post man!

[b_radlewis]

Originally Posted by BadThad

Couldn't resist, I'm in at $30.00....this is a good company from my DD and the PPS is way, way down near the 52-wk low.

Good fun. I am fighting for entry below 30.00.

[b_radlewis]

Alright in at 29.93.

[BadThad]

Warren Buffet owns SNY! Seems he is holding too from the latest disclosure:

Sanofi Aventis (NYSE: SNY) more than 3.9 million shares, SAME as before.

[Klipper22]

Sanofi-Aventis
174 Avenue de France
Cedex 13
Paris, 75635
France
Phone: 33 1 53 77 40 00
Fax: 33 1 53 77 44 63
Website: Sanofi-aventis - A diversified healthcare company, focused on patients? needs

Sector: Healthcare
Industry: Drug Manufacturers - Major
Full Time Employees: 104,867

Sanofi-Aventis, a healthcare company, engages in the discovery, development, and distribution of therapeutic solutions to improve the lives of everyone. It offers a range of healthcare assets, including a broad-based product portfolio in prescription drugs, OTC/OTX, generics, vaccines, and animal health. Sanofi-Aventis has a strategic alliance with Scripps Genomic Medicine for the purpose of research and development initiatives in the field of individualized medicine; and with Avila Therapeutics, Inc. to discover targeted covalent drugs for the treatment of cancers, as well as a joint venture with Hangzhou Minsheng Pharmaceutical Group Co. Ltd. to develop non-prescription drugs in China. The company was founded in 1970 and is headquartered in Paris, France.

Sanofi's chart should pull some support in the area of $31, but that is not why I am starting this thread. They have been trying to get Genzyme (NASDAQ:GENZ) to negotiate a merger for more than six months to no avail. They are back at it this week, so momo players may be keeping an eye on the companies over the next week for more significant news. Sounds like they may be bumping up their bid price for GENZ.

[Klipper22]

It was last August that French drug maker Sanofi-Aventis (NYSE:SNY) publicly disclosed that it had made an offer to buy Genzyme after approaching Genzyme (NASDAQ:GENZ) two months earlier in friendly merger discussions. The $18.5 billion bid represented a $69 per share offer, which at the time was at a nearly 40 percent premium to Genzyme’s share price before investors got wind of the merger talks and sent shares of GENZ surging north to the area of $70 in late July.

Negotiations at that time ended without any terms being reached as Sanofi’s CEO, Christopher Viehbacher described discussions as being thwarted by Genzyme’s management. In a letter to Genzyme’s CEO, Henri A. Termeer, Mr. Viebacher summarized the dialogue between the two companies as not moving forward because Mr. Termeer seemed to “remain unwilling to have constructive discussions.” Neither Mr. Termeer, nor Genzyme officials commented on the statement.

The Wall Street Journal broke a story this week that Sanofi is once again pursuing Genzyme and that the two companies financial representatives are back in merger discussions; this time with an increased value of $80 for each share of GENZ. Although not citing sources, WSJ reported that financial advisors for each company are meeting, but cautioned that this does not mean that a deal will happen.

In talks last year, it was reported that Genzyme had responded to the idea of a merger with a quick “no” before negotiations even began to discuss the price that Sanofi would be willing to offer. Discussions have always remained friendly with no signs of any sort of a hostile takeover, which would mean that Sanofi would take its price offer directly to the Genzyme shareholders.

The rationale behind motivation of either company has also not been disclosed. Sanofi had stated last year that it would continue to try and grow its company through acquisitions of some smaller biotechs, but clearly, Genzyme is not a small company, as it is a world leader in drugs for genetic diseases. The interest by Sanofi could be due to the fact that generic drugs are impacting sales of its lead drugs, Lovenox and Plavix, or could be related to its patent for Plavix being up next year. Sanofi could be looking to capitalize on late-stage drugs in development by Genzyme that, if approved, could be brought to market around the same time that it will lose its Plavix patent. Along with a host of drugs in its pipeline, Genzyme has Campath (alemtuzumab) for multiple sclerosis in Phase III clinical trials and mipomersen for cholesterol in late stage human trials as well.

The acquisition price has had no figures or terms verified, but Reuters did report that, according to its sources, the purchase price could include a contingent value right (CVR). A CVR is a type of right given to shareholders of an acquired company that ensures they receive additional benefit if a specified event occurs. In the case of Genzyme, it is believed that the CVR will be related to Campath reaching FDA approval and the amount of revenue that is generates over a specified period of time.

While speculation is ongoing, investors will be keeping a close eye on these companies and their relationship heading into the second trading week of 2011 for any word of a deal finalization approaching or even hints about the price structure being discussed.

[kiwidan]

My brother in law works for Sanofi and is being transfered to USA Pennsylvania.He can not discuss the reasons why but I am very curious.I can not find anything about Sanofi in Pennsylvania and was hoping someone here might be able to give me some ideas on where I can be looking.